Travere Therapeutics (TVTX) AI Stock Analysis

• Market Cap: $2.23B
• Dividend Yield: N/A
• Average Volume (3M): 2.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: 87.94%
• EPS Growth: 57.84%
• Country: US
• Employees: 385
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 89,138,670
• 10 Day Avg. Volume: 3,817,755
• 30 Day Avg. Volume: 2,329,381
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 4.18
• Enterprise Value/Gross Profit: 4.51
• Enterprise Value/Ebitda: -11.21
• 1Y Price Target: $35.54
• Price Target Upside: 51.43% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 49 Neutral
• Price Target: $17.50 ▼(-25.44% Downside)

Travere Therapeutics' overall stock score is primarily influenced by its financial performance challenges, including high debt levels and negative cash flows. While the earnings call provided positive insights into product performance and strategic progress, the company's valuation remains unattractive due to ongoing losses. Technical indicators suggest a neutral market sentiment, with no strong momentum in either direction.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Travere's products, enhancing its market position and supporting long-term financial health.

Regulatory Approval

The FDA's approval of updated REMS labeling for FILSPARI reduces monitoring burdens, potentially increasing patient adherence and expanding market reach.

Product Pipeline

The potential approval of FILSPARI for FSGS could establish Travere as a leader in treating this rare disease, opening new revenue streams.

Negative Factors

High Debt Levels

Significant leverage poses financial risks, potentially limiting Travere's ability to invest in growth opportunities and manage economic downturns.

Profitability Challenges

Ongoing losses and negative margins highlight profitability issues, which could affect Travere's ability to sustain operations without external funding.

Cash Flow Concerns

Negative cash flows indicate cash burn, which may pressure Travere's liquidity and necessitate additional financing to support operations.

Travere Therapeutics Business Overview & Revenue Model

Company Description

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

How the Company Makes Money

Travere Therapeutics generates revenue primarily through the sale of its approved pharmaceutical products, particularly Filspari, which is marketed for the treatment of IgA nephropathy. The company also earns revenue through collaborations and partnerships with other pharmaceutical companies, which may include milestone payments and royalties based on the sales of products developed in conjunction with these partners. Additionally, Travere may receive funding through grants and research contracts aimed at supporting its drug development initiatives.

Travere Therapeutics Financial Statement Overview

Summary

Travere Therapeutics demonstrates strong revenue growth and gross profit margins, but faces significant profitability and leverage challenges. The high debt levels and negative cash flows pose financial risks, requiring careful management to achieve sustainable growth and profitability.

Income Statement

Travere Therapeutics shows a strong gross profit margin of 92.69% TTM, indicating efficient cost management. However, the company faces challenges with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is positive at 22.06% TTM, suggesting potential for future improvement, but the consistent negative margins highlight profitability issues.

Balance Sheet

The company has a high debt-to-equity ratio of 12.20 TTM, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is low, suggesting limited equity financing relative to total assets.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn. However, the free cash flow to net income ratio is above 1, suggesting that cash outflows are somewhat aligned with accounting losses. The negative free cash flow growth rate of -32.51% TTM highlights increasing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	333.87M	233.18M	145.24M	212.02M	227.49M	198.32M
Gross Profit	309.47M	225.43M	133.79M	204.43M	220.71M	192.19M
EBITDA	-124.53M	-265.77M	-326.25M	-299.42M	-186.68M	-143.95M
Net Income	-169.06M	-321.55M	-111.40M	-278.48M	-180.09M	-169.43M
Balance Sheet
Total Assets	555.31M	594.13M	788.91M	672.59M	776.63M	607.44M
Cash, Cash Equivalents and Short-Term Investments	319.54M	370.70M	566.85M	450.25M	552.88M	361.59M
Total Debt	399.57M	401.58M	404.78M	407.49M	261.99M	215.34M
Total Liabilities	522.56M	535.05M	588.10M	629.73M	474.52M	396.23M
Stockholders Equity	32.75M	59.08M	200.81M	42.85M	302.11M	211.21M
Cash Flow
Free Cash Flow	-118.28M	-338.69M	-322.28M	-214.85M	-38.94M	-162.59M
Operating Cash Flow	-115.44M	-237.47M	-280.02M	-186.29M	-14.79M	-42.74M
Investing Cash Flow	11.96M	99.33M	55.78M	-32.55M	-137.62M	-61.33M
Financing Cash Flow	144.36M	139.42M	218.75M	117.57M	231.68M	127.71M

Travere Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.47
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVTX, the sentiment is Positive. The current price of 23.47 is above the 20-day moving average (MA) of 19.77, above the 50-day MA of 17.67, and above the 200-day MA of 18.15, indicating a bullish trend. The MACD of 1.90 indicates Negative momentum. The RSI at 64.08 is Neutral, neither overbought nor oversold. The STOCH value of 69.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TVTX.

Travere Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCR	68 Neutral	$1.78B	―	-5.38%	―	26.90%	62.72%
CGON	65 Neutral	$2.54B	―	-20.95%	―	―	―
Sector *	51 Neutral	$7.92B	-0.36	-43.38%	2.24%	22.38%	-2.16%
TVTX	49 Neutral	$2.23B	―	-705.73%	―	87.94%	57.84%
BCRX	48 Neutral	$1.69B	―	18.68%	―	45.85%	76.36%
IRON	43 Neutral	$2.08B	―	-26.36%	―	―	-22.19%
VERA	39 Underperform	$1.57B	―	-54.83%	―	―	-62.51%

Travere Therapeutics Corporate Events

Travere Therapeutics Holds Annual Meeting, Elects Directors

On May 15, 2025, Travere Therapeutics held its Annual Meeting where stockholders voted on several proposals. The company elected ten directors to serve until the 2026 Annual Meeting, approved an amendment to increase shares under the 2018 Equity Incentive Plan, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and strategic planning efforts.

The most recent analyst rating on (TVTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.

Travere Therapeutics’ FDA Acceptance for FILSPARI Application

On May 15, 2025, Travere Therapeutics announced that the FDA accepted its supplemental New Drug Application for FILSPARI® (sparsentan) for treating focal segmental glomerulosclerosis (FSGS), with a target action date set for January 13, 2026. If approved, FILSPARI could become the first FDA-approved treatment for FSGS, a rare kidney disorder affecting over 40,000 patients in the U.S. The application is supported by the Phase 3 DUPLEX Study and Phase 2 DUET Study, which demonstrated significant benefits in reducing proteinuria and improving remission rates in FSGS patients.

The most recent analyst rating on (TVTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.